Patents by Inventor Zena Werb

Zena Werb has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Novel Indications for Transforming Growth Factor-Beta Regulators
    Publication number: 20080206219
    Abstract: Methods, compounds and compositions for the modulation of TGF-? are disclosed wherein the vascular permeability in a subject is altered. The compounds can be antagonists or agonists, and can be oligonucleotides, antisense oligonucleotides, small molecules, antibodies, and the like. Compounds that modulate TGF-?, regulate TGF-? bioavailabililty, or the configuration and context of type 1 collagen can be used for the treatment or prevention of diseases caused by vascular permeability.
    Type: Application
    Filed: August 9, 2004
    Publication date: August 28, 2008
    Applicant: THE REGENCTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Lisa M. Coussens, Zena Werb
  • Use of matrix metalloproteinase inhibitors to mitigate nerve damage
    Publication number: 20030139332
    Abstract: This invention pertains to the discovery that inhibitors of matrix metalloproteinases (e.g. MMP-9) can reduce neurological damage (e.g. secondary damage) following trauma to nervous tissue in a mammal, and/or reduce abnormal vascular permeability associated with spinal cord injury, and/or improving recovery of neurological function following injury to neurological tissue. Methods of use of matrix metalloproteinase inhibitors for such applications are provided.
    Type: Application
    Filed: July 9, 2002
    Publication date: July 24, 2003
    Applicant: The Regents of the University of California
    Inventors: Linda Jeanne Noble, Frances Muriel Donovan, Zena Werb
  • Extracellular nonmitogenic angiogenesis factor and method of isolation thereof from wound fluid
    Patent number: 4503038
    Abstract: A nonmitogenic angiogenesis factor is isolated from wound fluid by dialysis to include materials in the molecular size range of 2,000 to 14,000, lyophilization, and chromatography. The nonmitogenic angiogenesis factor is identified by activity by corneal implant assay and by cell migration assay. The angiogenesis factor is also characterized by inactivity by mitogenesis assay.
    Type: Grant
    Filed: February 25, 1983
    Date of Patent: March 5, 1985
    Assignee: The Regents of the University of California
    Inventors: Michael J. Banda, Zena Werb, David R. Knighton, Thomas K. Hunt